Coronil biochemically inhibits the interaction of various clinically relevant mutants of SARS-CoV-2 Spike Proteins (Omicron Variants) with human ACE2 receptor Article Swipe
Acharya Balkrishna
,
Rishabh Dev
,
Sandeep Kumar
,
Anurag Varshney
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-4805471/v1
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-4805471/v1
Background Accumulating evidence suggests that the receptor binding domain (RBD) of the SARS-CoV-2 Omicron variant has several times more binding affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor compared to the RBD of the original covid-19 strain This increased binding affinity of Omicron variant is responsible for its increased internalization and infectivity.Methods In the present study, the impact of Coronil, a tri-herbal formulation of extracts from Withania somnifera, Tinospora cordifolia, and Ocimum sanctum on the binding properties of Omicron SARS-CoV-2 variant spike proteins (S proteins) was investigated. Compositional analysis of Coronil was performed by the Prominence-XR UHPLC system. The ELISA-based ACE2 binding inhibition assay was performed to delineate the effect of Coronil on the interaction between human ACE2 receptor and different Omicron variant spike proteins such as BA.4/BA5, XBB, BA.2.75.2, BA4.6/BF.7, BA.2.75.2, BQ.1.1, and a recently found spike protein variant JN.1 which is thought to emerge from BA.2.86.Results Coronil showed a dose-dependent inhibitory effect on the interactions between ACE2 and receptor binding domains (RBD) of all variants of spike proteins evaluated in this study including the recently emerged, highly transmissible variant spike protein JN.1. Although, Coronil significantly reduced the binding percentage in almost all the variant spike proteins, the maximum inhibition was achieved against BA.4/BA.5 where it inhibited the S protein – ACE2 interaction even at a low concentration of 3 µg/ml (16.6%). This binding inhibition was further increased to 60.3 and 84.6% at 100 and 300 µg/ml respectively.Conclusions This capability of Coronil to inhibit the binding of spike protein variants with ACE2 receptor may interfere with viral binding and internalization resulting in reduced infectivity of these Omicron spike protein variants. Overall, our data underscores the potential of Coronil in combating the various newly emerged Omicron spike protein variants. These findings may provide a basis for further studies of Coronil for its clinical effectiveness against these Omicron variants.
Related Topics
Concepts
Spike Protein
Spike (software development)
Mutant
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Receptor
Coronavirus disease 2019 (COVID-19)
Computational biology
2019-20 coronavirus outbreak
Chemistry
Biology
Virology
Genetics
Medicine
Gene
Computer science
Internal medicine
Software engineering
Outbreak
Disease
Infectious disease (medical specialty)
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-4805471/v1
- https://www.researchsquare.com/article/rs-4805471/latest.pdf
- OA Status
- gold
- References
- 47
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401734078
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401734078Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-4805471/v1Digital Object Identifier
- Title
-
Coronil biochemically inhibits the interaction of various clinically relevant mutants of SARS-CoV-2 Spike Proteins (Omicron Variants) with human ACE2 receptorWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-08-19Full publication date if available
- Authors
-
Acharya Balkrishna, Rishabh Dev, Sandeep Kumar, Anurag VarshneyList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-4805471/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-4805471/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-4805471/latest.pdfDirect OA link when available
- Concepts
-
Spike Protein, Spike (software development), Mutant, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Receptor, Coronavirus disease 2019 (COVID-19), Computational biology, 2019-20 coronavirus outbreak, Chemistry, Biology, Virology, Genetics, Medicine, Gene, Computer science, Internal medicine, Software engineering, Outbreak, Disease, Infectious disease (medical specialty)Top concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
47Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401734078 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-4805471/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-4805471/v1 |
| ids.openalex | https://openalex.org/W4401734078 |
| fwci | 0.0 |
| type | preprint |
| title | Coronil biochemically inhibits the interaction of various clinically relevant mutants of SARS-CoV-2 Spike Proteins (Omicron Variants) with human ACE2 receptor |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9993000030517578 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T10041 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.994700014591217 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | COVID-19 Clinical Research Studies |
| topics[2].id | https://openalex.org/T10211 |
| topics[2].field.id | https://openalex.org/fields/17 |
| topics[2].field.display_name | Computer Science |
| topics[2].score | 0.9858999848365784 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1703 |
| topics[2].subfield.display_name | Computational Theory and Mathematics |
| topics[2].display_name | Computational Drug Discovery Methods |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2909509916 |
| concepts[0].level | 5 |
| concepts[0].score | 0.7470033168792725 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q22329850 |
| concepts[0].display_name | Spike Protein |
| concepts[1].id | https://openalex.org/C2781390188 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7174577116966248 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q25203449 |
| concepts[1].display_name | Spike (software development) |
| concepts[2].id | https://openalex.org/C143065580 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6946452260017395 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3285695 |
| concepts[2].display_name | Mutant |
| concepts[3].id | https://openalex.org/C3007834351 |
| concepts[3].level | 5 |
| concepts[3].score | 0.5967744588851929 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q82069695 |
| concepts[3].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| concepts[4].id | https://openalex.org/C170493617 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5506139397621155 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[4].display_name | Receptor |
| concepts[5].id | https://openalex.org/C3008058167 |
| concepts[5].level | 4 |
| concepts[5].score | 0.50943523645401 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[5].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[6].id | https://openalex.org/C70721500 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4263136684894562 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[6].display_name | Computational biology |
| concepts[7].id | https://openalex.org/C3006700255 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4115634858608246 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q81068910 |
| concepts[7].display_name | 2019-20 coronavirus outbreak |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.37946730852127075 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C86803240 |
| concepts[9].level | 0 |
| concepts[9].score | 0.35500872135162354 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[9].display_name | Biology |
| concepts[10].id | https://openalex.org/C159047783 |
| concepts[10].level | 1 |
| concepts[10].score | 0.31297218799591064 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[10].display_name | Virology |
| concepts[11].id | https://openalex.org/C54355233 |
| concepts[11].level | 1 |
| concepts[11].score | 0.2600703835487366 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[11].display_name | Genetics |
| concepts[12].id | https://openalex.org/C71924100 |
| concepts[12].level | 0 |
| concepts[12].score | 0.16848117113113403 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[12].display_name | Medicine |
| concepts[13].id | https://openalex.org/C104317684 |
| concepts[13].level | 2 |
| concepts[13].score | 0.14618352055549622 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[13].display_name | Gene |
| concepts[14].id | https://openalex.org/C41008148 |
| concepts[14].level | 0 |
| concepts[14].score | 0.110237717628479 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[14].display_name | Computer science |
| concepts[15].id | https://openalex.org/C126322002 |
| concepts[15].level | 1 |
| concepts[15].score | 0.060048311948776245 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[15].display_name | Internal medicine |
| concepts[16].id | https://openalex.org/C115903868 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q80993 |
| concepts[16].display_name | Software engineering |
| concepts[17].id | https://openalex.org/C116675565 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q3241045 |
| concepts[17].display_name | Outbreak |
| concepts[18].id | https://openalex.org/C2779134260 |
| concepts[18].level | 2 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[18].display_name | Disease |
| concepts[19].id | https://openalex.org/C524204448 |
| concepts[19].level | 3 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[19].display_name | Infectious disease (medical specialty) |
| keywords[0].id | https://openalex.org/keywords/spike-protein |
| keywords[0].score | 0.7470033168792725 |
| keywords[0].display_name | Spike Protein |
| keywords[1].id | https://openalex.org/keywords/spike |
| keywords[1].score | 0.7174577116966248 |
| keywords[1].display_name | Spike (software development) |
| keywords[2].id | https://openalex.org/keywords/mutant |
| keywords[2].score | 0.6946452260017395 |
| keywords[2].display_name | Mutant |
| keywords[3].id | https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2 |
| keywords[3].score | 0.5967744588851929 |
| keywords[3].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| keywords[4].id | https://openalex.org/keywords/receptor |
| keywords[4].score | 0.5506139397621155 |
| keywords[4].display_name | Receptor |
| keywords[5].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[5].score | 0.50943523645401 |
| keywords[5].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[6].id | https://openalex.org/keywords/computational-biology |
| keywords[6].score | 0.4263136684894562 |
| keywords[6].display_name | Computational biology |
| keywords[7].id | https://openalex.org/keywords/2019-20-coronavirus-outbreak |
| keywords[7].score | 0.4115634858608246 |
| keywords[7].display_name | 2019-20 coronavirus outbreak |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.37946730852127075 |
| keywords[8].display_name | Chemistry |
| keywords[9].id | https://openalex.org/keywords/biology |
| keywords[9].score | 0.35500872135162354 |
| keywords[9].display_name | Biology |
| keywords[10].id | https://openalex.org/keywords/virology |
| keywords[10].score | 0.31297218799591064 |
| keywords[10].display_name | Virology |
| keywords[11].id | https://openalex.org/keywords/genetics |
| keywords[11].score | 0.2600703835487366 |
| keywords[11].display_name | Genetics |
| keywords[12].id | https://openalex.org/keywords/medicine |
| keywords[12].score | 0.16848117113113403 |
| keywords[12].display_name | Medicine |
| keywords[13].id | https://openalex.org/keywords/gene |
| keywords[13].score | 0.14618352055549622 |
| keywords[13].display_name | Gene |
| keywords[14].id | https://openalex.org/keywords/computer-science |
| keywords[14].score | 0.110237717628479 |
| keywords[14].display_name | Computer science |
| keywords[15].id | https://openalex.org/keywords/internal-medicine |
| keywords[15].score | 0.060048311948776245 |
| keywords[15].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-4805471/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-4805471/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-4805471/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5052860136 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-4749-6317 |
| authorships[0].author.display_name | Acharya Balkrishna |
| authorships[0].affiliations[0].raw_affiliation_string | Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[0].affiliations[1].raw_affiliation_string | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Acharya Balkrishna |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand, Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[1].author.id | https://openalex.org/A5015474669 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7878-6934 |
| authorships[1].author.display_name | Rishabh Dev |
| authorships[1].affiliations[0].raw_affiliation_string | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Rishabh Dev |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[2].author.id | https://openalex.org/A5100388883 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3440-3628 |
| authorships[2].author.display_name | Sandeep Kumar |
| authorships[2].affiliations[0].raw_affiliation_string | Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[2].affiliations[1].raw_affiliation_string | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Sandeep Kumar |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand, Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[3].author.id | https://openalex.org/A5051628387 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8509-0882 |
| authorships[3].author.display_name | Anurag Varshney |
| authorships[3].affiliations[0].raw_affiliation_string | Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[3].affiliations[1].raw_affiliation_string | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Anurag Varshney |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand, Rishabh Dev Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar-249405, Uttarakhand |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-4805471/latest.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Coronil biochemically inhibits the interaction of various clinically relevant mutants of SARS-CoV-2 Spike Proteins (Omicron Variants) with human ACE2 receptor |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9993000030517578 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W3135501652, https://openalex.org/W3207585454, https://openalex.org/W4291000693, https://openalex.org/W4394761436, https://openalex.org/W4243078506, https://openalex.org/W4372292428, https://openalex.org/W3017562527, https://openalex.org/W4205815969, https://openalex.org/W3023726384, https://openalex.org/W3045474919 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-4805471/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-4805471/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-4805471/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-4805471/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-4805471/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-4805471/v1 |
| publication_date | 2024-08-19 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4298146672, https://openalex.org/W4206057989, https://openalex.org/W4310208507, https://openalex.org/W4292182814, https://openalex.org/W4362520792, https://openalex.org/W4383550993, https://openalex.org/W3093225882, https://openalex.org/W3186935805, https://openalex.org/W4319293674, https://openalex.org/W4291890854, https://openalex.org/W4309686974, https://openalex.org/W4392761745, https://openalex.org/W4387843684, https://openalex.org/W4293206921, https://openalex.org/W4366992417, https://openalex.org/W4324130023, https://openalex.org/W4310828358, https://openalex.org/W4360610497, https://openalex.org/W4321172609, https://openalex.org/W4364365885, https://openalex.org/W4391453111, https://openalex.org/W4281641466, https://openalex.org/W3081477423, https://openalex.org/W4365149448, https://openalex.org/W3133896203, https://openalex.org/W3102114218, https://openalex.org/W3137081049, https://openalex.org/W4311380060, https://openalex.org/W4309338411, https://openalex.org/W3191083929, https://openalex.org/W4327681633, https://openalex.org/W3084666277, https://openalex.org/W4323364396, https://openalex.org/W4387996763, https://openalex.org/W3094279071, https://openalex.org/W4289653743, https://openalex.org/W4391466817, https://openalex.org/W4281939105, https://openalex.org/W4315649133, https://openalex.org/W4286214944, https://openalex.org/W4319938161, https://openalex.org/W4313488719, https://openalex.org/W4376872235, https://openalex.org/W4281754639, https://openalex.org/W4362507256, https://openalex.org/W4391539544, https://openalex.org/W4391989884 |
| referenced_works_count | 47 |
| abstract_inverted_index.2 | 27 |
| abstract_inverted_index.3 | 222 |
| abstract_inverted_index.S | 211 |
| abstract_inverted_index.a | 62, 136, 152, 218, 295 |
| abstract_inverted_index.(S | 85 |
| abstract_inverted_index.In | 54 |
| abstract_inverted_index.as | 128 |
| abstract_inverted_index.at | 217, 235 |
| abstract_inverted_index.by | 95 |
| abstract_inverted_index.in | 173, 193, 264, 281 |
| abstract_inverted_index.is | 46, 144 |
| abstract_inverted_index.it | 208 |
| abstract_inverted_index.of | 11, 34, 43, 60, 65, 79, 91, 112, 166, 169, 221, 243, 249, 267, 279, 300 |
| abstract_inverted_index.on | 75, 114, 156 |
| abstract_inverted_index.to | 22, 31, 108, 146, 231, 245 |
| abstract_inverted_index.100 | 236 |
| abstract_inverted_index.300 | 238 |
| abstract_inverted_index.RBD | 33 |
| abstract_inverted_index.The | 100 |
| abstract_inverted_index.all | 167, 195 |
| abstract_inverted_index.and | 52, 72, 121, 135, 161, 233, 237, 261 |
| abstract_inverted_index.for | 48, 297, 302 |
| abstract_inverted_index.has | 16 |
| abstract_inverted_index.its | 49, 303 |
| abstract_inverted_index.low | 219 |
| abstract_inverted_index.may | 256, 293 |
| abstract_inverted_index.our | 274 |
| abstract_inverted_index.the | 6, 12, 23, 32, 35, 55, 58, 76, 96, 110, 115, 157, 177, 190, 196, 200, 210, 247, 277, 283 |
| abstract_inverted_index.was | 87, 93, 106, 203, 228 |
| abstract_inverted_index.– | 213 |
| abstract_inverted_index.60.3 | 232 |
| abstract_inverted_index.ACE2 | 102, 119, 160, 214, 254 |
| abstract_inverted_index.JN.1 | 142 |
| abstract_inverted_index.This | 39, 225, 241 |
| abstract_inverted_index.XBB, | 130 |
| abstract_inverted_index.data | 275 |
| abstract_inverted_index.even | 216 |
| abstract_inverted_index.from | 67, 148 |
| abstract_inverted_index.more | 19 |
| abstract_inverted_index.such | 127 |
| abstract_inverted_index.that | 5 |
| abstract_inverted_index.this | 174 |
| abstract_inverted_index.with | 253, 258 |
| abstract_inverted_index.(RBD) | 10, 165 |
| abstract_inverted_index.84.6% | 234 |
| abstract_inverted_index.JN.1. | 185 |
| abstract_inverted_index.These | 291 |
| abstract_inverted_index.UHPLC | 98 |
| abstract_inverted_index.assay | 105 |
| abstract_inverted_index.basis | 296 |
| abstract_inverted_index.found | 138 |
| abstract_inverted_index.human | 24, 118 |
| abstract_inverted_index.newly | 285 |
| abstract_inverted_index.spike | 83, 125, 139, 170, 183, 198, 250, 270, 288 |
| abstract_inverted_index.study | 175 |
| abstract_inverted_index.these | 268, 307 |
| abstract_inverted_index.times | 18 |
| abstract_inverted_index.viral | 259 |
| abstract_inverted_index.where | 207 |
| abstract_inverted_index.which | 143 |
| abstract_inverted_index.(ACE2) | 28 |
| abstract_inverted_index.Ocimum | 73 |
| abstract_inverted_index.almost | 194 |
| abstract_inverted_index.domain | 9 |
| abstract_inverted_index.effect | 111, 155 |
| abstract_inverted_index.emerge | 147 |
| abstract_inverted_index.enzyme | 26 |
| abstract_inverted_index.highly | 180 |
| abstract_inverted_index.impact | 59 |
| abstract_inverted_index.showed | 151 |
| abstract_inverted_index.strain | 38 |
| abstract_inverted_index.study, | 57 |
| abstract_inverted_index.µg/ml | 223, 239 |
| abstract_inverted_index.BQ.1.1, | 134 |
| abstract_inverted_index.Coronil | 92, 113, 150, 187, 244, 280, 301 |
| abstract_inverted_index.Omicron | 14, 44, 80, 123, 269, 287, 308 |
| abstract_inverted_index.against | 205, 306 |
| abstract_inverted_index.between | 117, 159 |
| abstract_inverted_index.binding | 8, 20, 41, 77, 103, 163, 191, 226, 248, 260 |
| abstract_inverted_index.domains | 164 |
| abstract_inverted_index.emerged | 286 |
| abstract_inverted_index.further | 229, 298 |
| abstract_inverted_index.inhibit | 246 |
| abstract_inverted_index.maximum | 201 |
| abstract_inverted_index.present | 56 |
| abstract_inverted_index.protein | 140, 184, 212, 251, 271, 289 |
| abstract_inverted_index.provide | 294 |
| abstract_inverted_index.reduced | 189, 265 |
| abstract_inverted_index.several | 17 |
| abstract_inverted_index.studies | 299 |
| abstract_inverted_index.system. | 99 |
| abstract_inverted_index.thought | 145 |
| abstract_inverted_index.variant | 15, 45, 82, 124, 141, 182, 197 |
| abstract_inverted_index.various | 284 |
| abstract_inverted_index.(16.6%). | 224 |
| abstract_inverted_index.Coronil, | 61 |
| abstract_inverted_index.Overall, | 273 |
| abstract_inverted_index.achieved | 204 |
| abstract_inverted_index.affinity | 21, 42 |
| abstract_inverted_index.analysis | 90 |
| abstract_inverted_index.clinical | 304 |
| abstract_inverted_index.compared | 30 |
| abstract_inverted_index.covid-19 | 37 |
| abstract_inverted_index.emerged, | 179 |
| abstract_inverted_index.evidence | 3 |
| abstract_inverted_index.extracts | 66 |
| abstract_inverted_index.findings | 292 |
| abstract_inverted_index.original | 36 |
| abstract_inverted_index.proteins | 84, 126, 171 |
| abstract_inverted_index.recently | 137, 178 |
| abstract_inverted_index.receptor | 7, 29, 120, 162, 255 |
| abstract_inverted_index.suggests | 4 |
| abstract_inverted_index.variants | 168, 252 |
| abstract_inverted_index.Although, | 186 |
| abstract_inverted_index.BA.4/BA.5 | 206 |
| abstract_inverted_index.BA.4/BA5, | 129 |
| abstract_inverted_index.Tinospora | 70 |
| abstract_inverted_index.combating | 282 |
| abstract_inverted_index.delineate | 109 |
| abstract_inverted_index.different | 122 |
| abstract_inverted_index.evaluated | 172 |
| abstract_inverted_index.including | 176 |
| abstract_inverted_index.increased | 40, 50, 230 |
| abstract_inverted_index.inhibited | 209 |
| abstract_inverted_index.interfere | 257 |
| abstract_inverted_index.performed | 94, 107 |
| abstract_inverted_index.potential | 278 |
| abstract_inverted_index.proteins) | 86 |
| abstract_inverted_index.proteins, | 199 |
| abstract_inverted_index.resulting | 263 |
| abstract_inverted_index.variants. | 272, 290, 309 |
| abstract_inverted_index.BA.2.75.2, | 131, 133 |
| abstract_inverted_index.SARS-CoV-2 | 13, 81 |
| abstract_inverted_index.capability | 242 |
| abstract_inverted_index.inhibition | 104, 202, 227 |
| abstract_inverted_index.inhibitory | 154 |
| abstract_inverted_index.percentage | 192 |
| abstract_inverted_index.properties | 78 |
| abstract_inverted_index.somnifera, | 69 |
| abstract_inverted_index.tri-herbal | 63 |
| abstract_inverted_index.BA4.6/BF.7, | 132 |
| abstract_inverted_index.ELISA-based | 101 |
| abstract_inverted_index.cordifolia, | 71 |
| abstract_inverted_index.formulation | 64 |
| abstract_inverted_index.infectivity | 266 |
| abstract_inverted_index.interaction | 116, 215 |
| abstract_inverted_index.responsible | 47 |
| abstract_inverted_index.underscores | 276 |
| abstract_inverted_index.Accumulating | 2 |
| abstract_inverted_index.interactions | 158 |
| abstract_inverted_index.Compositional | 89 |
| abstract_inverted_index.Prominence-XR | 97 |
| abstract_inverted_index.concentration | 220 |
| abstract_inverted_index.effectiveness | 305 |
| abstract_inverted_index.investigated. | 88 |
| abstract_inverted_index.significantly | 188 |
| abstract_inverted_index.transmissible | 181 |
| abstract_inverted_index.dose-dependent | 153 |
| abstract_inverted_index.internalization | 51, 262 |
| abstract_inverted_index.<italic>Withania | 68 |
| abstract_inverted_index.sanctum</italic> | 74 |
| abstract_inverted_index.angiotensin-converting | 25 |
| abstract_inverted_index.<bold>Background</bold> | 1 |
| abstract_inverted_index.<title>Abstract</title> | 0 |
| abstract_inverted_index.BA.2.86.<bold>Results</bold> | 149 |
| abstract_inverted_index.infectivity.<bold>Methods</bold> | 53 |
| abstract_inverted_index.respectively.<bold>Conclusions</bold> | 240 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 4 |
| citation_normalized_percentile.value | 0.20383538 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |